Feb 8, 2021: Read all about UK’s Systemic Anti-Cancer Therapy (SACT) Database

The SACT database is a population-based resource of SACT activity reported routinely by National Health Service (NHS) trusts in England. Data are collected since 2012 on the SACT treatments of adult and paediatric patients, delivered in secondary and tertiary settings with the intention of improving survival, delaying further cancer progression or development and improving disease-free or progression-free survival.

Systemic Anti-Cancer Therapy Database (SACT) (United Kingdom) **

Database Contact Data

SACT
UNITED KINGDOM
Email 1: ndrs.datasets@nhs.net
Email 2: NDRSenquiries@nhs.net
Website: www.chemodataset.nhs.uk
Phone: +44 0113 518 0696

Alternate Contact

Contact form: https://digital.nhs.uk/ndrs/ndrs-contact-page

References of Studies Using/Describing Database

1. Tabacchi F, Oberai R, Parmar K, Oxley L, Coe S, Iatridi V, Tammam J, Watson E, Wanstall H. Documentation of anthropometrics in people with cancer: a cross-site collaboration audit in four hospital settings in the UK. Support Care Cancer. 2024 Oct 10;32(11):720.

2. Han L, Josephs D, Boyle J, Sullivan R, Rigg A, van der Meulen J, Aggarwal A. Hospital Factors Influencing the Mobility of Patients for Systemic Therapies in Breast and Bowel Cancer in the Metastatic Setting: A National Population-based Evaluation. Clin Oncol (R Coll Radiol). 2024 Oct;36(10):e398-e407.

3. Lythgoe MP, Emhardt AJ, Naci H, Krell J, Sullivan R, Aggarwal A. Efficacy and safety of interim oncology treatments introduced for solid cancers during the COVID-19 pandemic in England: a retrospective evidence-based analysis. Lancet Reg Health Eur. 2024 Sep 10;46:101062.

4. Wills L, Nagarwalla D, Pearson C, McPhail S, Hinchliffe R, Sharpless B, Fardus-Reid F, Ambler L, Harrison S, Shelton J. Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis. Eur J Health Econ. 2024 Jul;25(5):763-774.

5. Hughes NF, Cromie KJ, Feltbower RG, McCabe MG, Stark D. Delivered relative dose intensity in adolescent and young adult germ cell tumours in England: Assessment of data quality and consistency from clinical trials compared to national cancer registration data. Int J Cancer. 2024 Mar 1;154(5):816-829.

6. Norris RP, Dew R, Greystoke A, Todd A, Sharp L. Socio-economic Inequalities in Novel NSCLC Treatments During the Era of Tumor Biomarker Guided Therapy: A Population-based Cohort Study in a Publicly Funded Healthcare System. J Thorac Oncol. 2023 May 3:S1556-0864(23)00522-1.

7. Gannon MR, Park MH, Miller K, Dodwell D, Horgan K, Clements K, Medina J, Cromwell DA. Concordance of cancer drug therapy information derived from routinely collected hospital admissions data and the Systemic Anti-Cancer Therapy (SACT) dataset, for older women diagnosed with early invasive breast cancer in England. Cancer Epidemiol. 2023 Apr;83:102337. 

8. Kang J, Cairns J. "Don't Think Twice, It's All Right": Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England. Pharmacoecon Open. 2023 Jan;7(1):77-91.

9. Hassan S, Miles A, Rachet B, Morris M. Variations in the Type of Adjuvant Chemotherapy Among Stage III Colon Cancer Patients in England. J Gastrointest Cancer. 2023 Jan 5. doi: 10.1007/s12029-022-00899-9. Epub ahead of print. PMID: 36602753.

10. Board R, Smittenaar R, Lawton S, Liu H, Juwa B, Chao D, Corrie P. Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018. International Journal of Cancer. 2021 Feb 15;148(4):868-75.  

1/27/21 Read all about the Singapore Cancer Registry on B.R.I.D.G.E. TO DATA

The Singapore Cancer Registry (SCR), one of the oldest and most established registries, was set up in 1968 to provide information on cancer trends in Singapore. Over the last 50+ years, SCR, a comprehensive, population-based national cancer registry, has collated data on all cancers by histological diagnosis as well as notification by doctors through clinical assessment in Singapore.

Singapore Cancer Registry (Singapore) **

Database Contact Data

National Registry of Diseases Office
Address:
Health Promotion Board
3 Second Hospital Avenue
Level 5
Singapore 168937
Email: HPB_SERVICENRDO@hpb.gov.sg
Phone: +65 6435 3077 / +65 6435 3091 / +65 6435 3039

Alternate Contact

N/A

References of Studies Using/Describing Database

1. Health Promotion Board. Singapore Cancer Registry
Annual Report 2022. 2024 Sep. https://www.nrdo.gov.sg/docs/librariesprovider3/default-document-library/scr-ar-2022_web-report.pdf?sfvrsn=a9eb8c10_1

2. Thomas CE, Adibi JJ, Kuipers AL, Diergaarde B, Luu HN, Jin A, Koh WP, Gao YT, Adams-Haduch J, Wang R, Lokshin A. Soluble CD137 and risk of hepatocellular carcinoma: nested case–control studies in cohorts in Shanghai and Singapore. British Journal of Cancer. 2023 Jun 15;128(11):2081-8.

3. Peres MA, Huihua L, Antunes JL, Perea LM, Iyer NG, Peres KG. Time trend and Age-Period-Cohort analysis of potentially HPV-related oral and pharyngeal cancer incidence in Singapore between 1968 and 2017. Oral Oncology. 2023 Jan 1;136:106272.

4. Yu YC, Paragomi P, Jin A, Wang R, Schoen RE, Koh WP, Yuan JM, Luu HN. Dietary nonstarch polysaccharide intake and risk of colorectal cancer: findings from the Singapore Chinese health study. Cancer research communications. 2022 Oct 31;2(10):1304-11.

5. Soo R, Mery L, Bardot A, Kanesvaran R, Keong TC, Pongnikorn D, Prasongsook N, Hutajulu SH, Irawan C, Ab Manan A, Thiagarajan M. Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. ESMO open. 2022 Oct 1;7(5):100560.

6. Htun HL, Lian W, Wong J, Tan EJ, Foo LL, Ong KH, Lim WY. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017. Cancer Epidemiology. 2022 Aug 1;79:102175.

7. Sheng LT, Jiang YW, Pan A, Koh WP. Dietary total antioxidant capacity and mortality outcomes: The Singapore Chinese Health Study. European Journal of Nutrition. 2022 Aug;61(5):2375-82.

8. Lei M, Adambekov S, Edwards RP, Wang R, Yuan JM, Kalix E, Lopa S, Linkov F. Endometrial cancer risk factors in Singapore Chinese: a prospective cohort study. Annals of Epidemiology. 2022 Jul 1;71:9-14.

9. Paragomi P, Wang R, Jin A, Yu YC, Brand RE, Sheng LT, Pan A, Koh WP, Yuan JM, Luu H. Composite dietary antioxidant index and the risk of pancreatic cancer: Findings from a prospective cohort study. Cancer Research. 2022 Jun 15;82(12_Supplement):3667-.

10. Yu YC, Paragomi P, Wang R, Jin A, Schoen RE, Sheng LT, Pan A, Koh WP, Yuan JM, Luu HN. Composite dietary antioxidant index and the risk of colorectal cancer: findings from the Singapore Chinese Health Study. International Journal of Cancer. 2022 May 15;150(10):1599-608.

10. Tan TH, Zheng H, Cheo T, Tey J, Soon YY. Risk of Stroke in Nasopharyngeal Cancer Survivors: A National Registry-Based Population Cohort Study. Neurology. 2022 Jan 11;98(2):e115-24.

Subscribe to